Continuous glucose monitoring linked to lower mortality in insulin-treated type 2 diabetes

An analysis presented at the European Association for the Study of Diabetes meeting in Milan found that type 2 diabetes patients using continuous glucose monitoring (CGM) while on basal insulin had a 44% lower risk of death after one year compared to those not using CGM. After two years, the mortality risk reduction remained significant at 35%. This data highlights the potential benefits of CGM in managing type 2 diabetes with insulin therapy.

Originally published by gnews